Advances in platinum-based drug development for cervical cancer therapy
- 1School of Chemistry and Environmental Engineering, Changchun University of Science and Technology
- 2Institute of Physical Organic Chemistry, National Academy of Sciences of Belarus
- 3Department of Obstetrics and Gynecology, Wenling Maternal and Child Healthcare Hospital
Abstract
Cervical cancer remains a predominant malignancy of the female reproductive system and a critical global health challenge. Traditional platinum-based agents such as cisplatin, carboplatin, and oxaliplatin, are cornerstones in postoperative adjuvant therapy, management of locally advanced cases, and systemic treatment of recurrent/metastatic disease. However, their clinical efficacy is frequently hampered by severe systemic toxicities and the emergence of chemoresistance. To address these bottlenecks, diverse nano-delivery platforms have been engineered to enhance bioavailability and mitigate adverse effects. This review systematically delineates the evolution of first-to third-generation platinum drugs, elucidating their molecular mechanisms of action specifically within the landscape of cervical cancer. Furthermore, we critically evaluate the clinical application of these agents and provide a comprehensive synthesis of recent advances in nano-delivery systems, including targeted and stimuli-responsive carriers. By bridging traditional pharmacology with cutting-edge nanotechnology, this review offers strategic insights into achieving precise delivery and controlled release, potentially defining new paradigms for the next-generation of cervical cancer therapeutics.
Related
- Combined Active Bone Marrow‐Sparing Radiotherapy and Prophylactic PEG‐rhG‐CSF to Reduce Severe Neutropenia During Platinum‐Doublet Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer: A Phase II Trial
- Intensity-modulated radiotherapy combined with albumin-bound paclitaxel and platinum-based chemotherapy for locoregional recurrent cervical cancer: a single-institutional phase II investigator-initiated nonrandomized clinical trial
- Advances in γδ T cell-mediated immune surveillance in cervical cancer
- Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial
- Development and validation of a machine learning-based prediction model for anemia risk in patients with primary lung cancer receiving platinum-based chemotherapy: a multicenter study
BibTeX
@article{shao2026advances,
title = {{Advances in platinum-based drug development for cervical cancer therapy}},
author = {Donghan Shao and Ping Gao and Qian Wang and Yuqin Ma and Irina Kolesnik and Vladimir Potkin and Leijiao Li and Yongjun Teng},
journal = {Frontiers in Pharmacology},
year = {2026},
month = oct,
doi = {10.3389/fphar.2026.1794356},
url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.1794356/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Advances in platinum-based drug development for cervical cancer therapy
AU - Donghan Shao
AU - Ping Gao
AU - Qian Wang
AU - Yuqin Ma
AU - Irina Kolesnik
AU - Vladimir Potkin
AU - Leijiao Li
AU - Yongjun Teng
PY - 2026
DA - 2026/10/28
JO - Frontiers in Pharmacology
DO - 10.3389/fphar.2026.1794356
UR - https://www.frontiersin.org/articles/10.3389/fphar.2026.1794356/full
AB - Cervical cancer remains a predominant malignancy of the female reproductive system and a critical global health challenge. Traditional platinum-based agents such as cisplatin, carboplatin, and oxaliplatin, are cornerstones in postoperative adjuvant therapy, management of locally advanced cases, and systemic treatment of recurrent/metastatic disease. However, their clinical efficacy is frequently hampered by severe systemic toxicities and the emergence of chemoresistance. To address these bottlenecks, diverse nano-delivery platforms have been engineered to enhance bioavailability and mitigate adverse effects. This review systematically delineates the evolution of first-to third-generation platinum drugs, elucidating their molecular mechanisms of action specifically within the landscape of cervical cancer. Furthermore, we critically evaluate the clinical application of these agents and provide a comprehensive synthesis of recent advances in nano-delivery systems, including targeted and stimuli-responsive carriers. By bridging traditional pharmacology with cutting-edge nanotechnology, this review offers strategic insights into achieving precise delivery and controlled release, potentially defining new paradigms for the next-generation of cervical cancer therapeutics.
SN - 1663-9812
ER -